Profile
Doris Peterkin is the founder of OncoPep, Inc. since 2010, where she currently holds the title of Chief Executive Officer & Director.
She is also a former President & Chief Executive Officer of Healagenics, Inc.
Doris Peterkin active positions
| Companies | Position | Start |
|---|---|---|
OncoPep, Inc.
 OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Founder | 01/01/2010 |
Former positions of Doris Peterkin
| Companies | Position | End |
|---|---|---|
Healagenics, Inc.
 Healagenics, Inc. Medical SpecialtiesHealth Technology Healagenics, Inc. is dedicated to developing innovative products for advanced wound care that have the potential to help people every day who are suffering and at risk for further serious medical complications. The company's initial product, the FDA-cleared Healadex®, is the first to use porcine serum in moist wound dressings for the treatment of acute and chronic wounds. Healagenics continues to develop groundbreaking products for both clinician use and over-the-counter sales in the treatment of wound care. Founded in 2006, Healagenics is a privately-held biomedical technology company headquartered in Woburn, Massachusetts. | President | 17/01/2011 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Finance |
Healagenics, Inc.
Healagenics, Inc. Medical SpecialtiesHealth Technology Healagenics, Inc. is dedicated to developing innovative products for advanced wound care that have the potential to help people every day who are suffering and at risk for further serious medical complications. The company's initial product, the FDA-cleared Healadex®, is the first to use porcine serum in moist wound dressings for the treatment of acute and chronic wounds. Healagenics continues to develop groundbreaking products for both clinician use and over-the-counter sales in the treatment of wound care. Founded in 2006, Healagenics is a privately-held biomedical technology company headquartered in Woburn, Massachusetts. | Health Technology |
- Stock Market
- Insiders
- Doris Peterkin
